A Single-Arm, Single-Center, Open-Label Phase I Clinical Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of Autologous Tumor-Reactive T Cells(GK02) Derived From Malignant Ascites Caused by Advanced Solid Tumors
Latest Information Update: 03 Feb 2026
At a glance
- Drugs GK 02 (Primary)
- Indications Malignant ascites
- Focus Adverse reactions
- Sponsors Beijing Geekgene Technology
Most Recent Events
- 03 Feb 2026 New trial record